Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease
source: Cochrane Database of Systematic Reviews
year: 2017
authors: Owusu-Ofori S, Remmington T
summary/abstract:Background:
Acute splenic sequestration crises are a complication of sickle cell disease, with high mortality rates and frequent recurrence in survivors of first attacks. Splenectomy and blood transfusion, with their consequences, are the mainstay of long-term management used in different parts of the world. This is a 2017 update of a Cochrane Review first published in 2002, and previously updated, most recently in 2015.
Objectives:
To assess whether splenectomy (total or partial), to prevent acute splenic sequestration crises in people with sickle cell disease, improved survival and decreased morbidity in people with sickle cell disease, as compared with regular blood transfusions.
Main Results:
No trials of splenectomy for acute splenic sequestration were found.
Author’s conclusion:
Splenectomy, if full, will prevent further sequestration and if partial, may reduce the recurrence of acute splenic sequestration crises. However, there is a lack of evidence from trials showing that splenectomy improves survival and decreases morbidity in people with sickle cell disease. There is a need for a well-designed, adequately-powered, randomized controlled trial to assess the benefits and risks of splenectomy compared to transfusion programmes, as a means of improving survival and decreasing mortality from acute splenic sequestration in people with sickle cell disease.There are no trials included in the review and we have not identified any relevant trials up to August 2017. We will continue to run searches to identify any potentially relevant trials; however, we do not plan to update other sections of the review until new trials are published.
DOI: 10.1002/14651858.CD003425.pub4
read more full text
Related Content
-
2017 SiNERGe Webinar July 14 – Chronic Opioid Therapy & Sickle Cell Diseasehttps://www.youtube.com/watch?v=8WZNTwPD...
-
Global Blood Therapeutics Announces Completion of Safety Review by Independent Data and Safety Monitoring Board (DSM...Global Blood Therapeutics, Inc. (GBT) (N...
-
Beyond Hydroxyurea: New and Old Drugs in the Pipeline for Sickle Cell DiseaseDespite Food and Drug Administration (FD...
-
Acute kidney injury in children with sickle cell disease-compounding a chronic problemIn an article recently published in Pedi...
-
Hospital Playroom Transformed Into Romantic Restaurant For Parents Of Kids With Bone Marrow TransplantsIt was Valentine’s Day with a lot of h...
-
Gene-Edited ‘Supercells’ Make Progress In Fight Against Sickle Cell DiseaseDoctors are reporting the first evidence...
-
Siklos®, the first and only hydroxyurea-based treatment for pediatric patients with sickle cell anemia, now availab...Medunik USA, a company dedicated to impr...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.